Two Sigma Advisers Reduces $4M in Cerus Corporation ($CERS)

Key Points

  • Two Sigma Advisers changed its Cerus Corporation ($CERS) stake by 100.0% last quarter, cutting to 0 shares.
  • Wall Street's consensus rating on $CERS is Strong Buy and an average price target of $4.67.
  • $CERS last traded around $2.59.

Two Sigma Advisers reduced its position in Cerus Corporation ($CERS), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of Cerus Corporation after selling 1,397,900 shares during the quarter.

Cerus Corporation ($CERS) Stock

Last price$2.59
Market cap$512.94M
Beta1.77
52-week low$1.15
52-week high$3.15
50-day MA$2.37
200-day MA$1.99
Current ratio1.63
Quick ratio1.02
Debt-to-equity1.43

Cerus Corporation Earnings

EPS (ttm)$-0.05
Revenue (ttm)$216.56M
Revenue growth24.1%
Net margin-4.4%
Return on equity-15.4%
Next earningsApr 30, 2026

Analysts Set New Price Targets

ConsensusStrong Buy
Average target$4.67
High target$5.00
Low target$4.00
Analysts covering3

About Cerus Corporation

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.

ExchangeNasdaqGM
SectorHealthcare
IndustryMedical Devices
HeadquartersConcord, CA
CEOMr. William M. Greenman
Employees261

See Also

This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.